


Newly Reported Substances: The following substances were reported to NFLIS-Drug for the first time between **October 1, 2022, and December 31, 2022.**




South


Flubrotizolam



N-Cyclohexyl-*N*-methylmethylone




N-Isopropylbutylone




Midwest

South and Midwest

2-Fluoro-2-oxo PCE





N-Desethyl isotonitazene




South, Midwest, and Northeast

MDMB-INACA



Northeast

Cyclazodone



Snapshot of Drug Reports Received by NFLIS-Drug


The tables on the right present the top drug reports in each category received by NFLIS-Drug between October 1, 2022, and December 31, 2022.

Synthetic Cannabinoids	968	Synthetic Cathinones	1,985	Benzodiazepines	5,559
MDMB-4en-PINACA	351	Dipentylone	1,271	Alprazolam	2,581
ADB-BUTINACA	191	Eutylone	264	Clonazepam	971
CH-PIATA	35	alpha-PiHP	164	Clonazolam	494
ADB-FUBIATA	29	<i>N</i> -Cyclohexylmethylone	75	Bromazolam	416
Fluoro-MDMB-PICA ¹	29	alpha-PHP	47	Diazepam	306


Depressants and Tranquilizers	3,426	Psychedelics	2,987
Xylazine	2,025	Psilocin	1,479
Phencyclidine (PCP)	557	Lysergic acid diethylamide (LSD)	695
Ketamine	377	Psilocin/psilocybin	537
Cyclobenzaprine	92	Psilocybin	274
Carisoprodol	80		

¹ Includes all positional and nonspecified isomers as reported by participating laboratories.


Upward Trends, by Date Submitted to Laboratory



Oxycodone



Dipentylone



Medetomidine

Note: A reliable percentage for December 2022 could not be calculated because of the small proportion of expected total reports received by NFLIS-Drug at the time of analysis.

Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in January 2023. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after October 1, 2021. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.dea/diversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.dea/diversion.usdoj.gov/publicationsRedesign.xhtml>. Questions and comments: NFLIS@dea.gov

